These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 38152659)
1. Hippo/YAP signaling pathway: a new therapeutic target for diabetes mellitus and vascular complications. Wei L; Gao J; Wang L; Tao Q; Tu C Ther Adv Endocrinol Metab; 2023; 14():20420188231220134. PubMed ID: 38152659 [TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP/TAZ activation. Feng L; Chen Y; Li N; Yang X; Zhou L; Li H; Wang T; Xie M; Liu H Life Sci; 2023 Jun; 322():121671. PubMed ID: 37023953 [TBL] [Abstract][Full Text] [Related]
3. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. Juan WC; Hong W Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805 [TBL] [Abstract][Full Text] [Related]
4. Hippo signaling pathway and respiratory diseases. Tang W; Li M; Yangzhong X; Zhang X; Zu A; Hou Y; Li L; Sun S Cell Death Discov; 2022 Apr; 8(1):213. PubMed ID: 35443749 [TBL] [Abstract][Full Text] [Related]
5. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ). Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650 [TBL] [Abstract][Full Text] [Related]
6. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity. Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865 [TBL] [Abstract][Full Text] [Related]
7. YAP/TAZ: a promising target for squamous cell carcinoma treatment. Dong X; Meng L; Liu P; Ji R; Su X; Xin Y; Jiang X Cancer Manag Res; 2019; 11():6245-6252. PubMed ID: 31360073 [TBL] [Abstract][Full Text] [Related]
8. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway. Jang JW; Kim MK; Bae SC Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552 [TBL] [Abstract][Full Text] [Related]
9. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H Front Oncol; 2021; 11():700315. PubMed ID: 34395269 [TBL] [Abstract][Full Text] [Related]
10. The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling. Xu Q; Zhuo K; Zhang X; Zhen Y; Liu L; Zhang L; Gu Y; Jia H; Chen Q; Liu M; Dong J; Zhou MS Eur J Pharmacol; 2024 Jan; 962():176252. PubMed ID: 38061470 [TBL] [Abstract][Full Text] [Related]
11. Activation of Yes-Associated Protein/PDZ-Binding Motif Pathway Contributes to Endothelial Dysfunction and Vascular Inflammation in AngiotensinII Hypertension. Xu Q; Zhuo K; Cai R; Su X; Zhang L; Liu Y; Zhu L; Ren F; Zhou MS Front Physiol; 2021; 12():732084. PubMed ID: 34650444 [TBL] [Abstract][Full Text] [Related]
12. Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis. Boopathy GTK; Hong W Front Cell Dev Biol; 2019; 7():49. PubMed ID: 31024911 [TBL] [Abstract][Full Text] [Related]
13. YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis. Cho H; Kim J; Ahn JH; Hong YK; Mäkinen T; Lim DS; Koh GY Circ Res; 2019 Jan; 124(2):225-242. PubMed ID: 30582452 [TBL] [Abstract][Full Text] [Related]
14. Targeting mammalian serine/threonine-protein kinase 4 through Yes-associated protein/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchestrated renal fibrosis. Yang T; Heng C; Zhou Y; Hu Y; Chen S; Wang H; Yang H; Jiang Z; Qian S; Wang Y; Wang J; Zhu X; Du L; Yin X; Lu Q Metabolism; 2020 Jul; 108():154258. PubMed ID: 32376130 [TBL] [Abstract][Full Text] [Related]
15. Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases. Yu Y; Su X; Qin Q; Hou Y; Zhang X; Zhang H; Jia M; Chen Y Pharmacol Res; 2020 Sep; 159():105009. PubMed ID: 32553712 [TBL] [Abstract][Full Text] [Related]
16. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1. Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213 [TBL] [Abstract][Full Text] [Related]
17. TGF-β/Smads signaling pathway, Hippo-YAP/TAZ signaling pathway, and VEGF: Their mechanisms and roles in vascular remodeling related diseases. Liu H; Sun M; Wu N; Liu B; Liu Q; Fan X Immun Inflamm Dis; 2023 Nov; 11(11):e1060. PubMed ID: 38018603 [TBL] [Abstract][Full Text] [Related]
18. The Hippo signaling pathway: a potential therapeutic target is reversed by a Chinese patent drug in rats with diabetic retinopathy. Hao GM; Lv TT; Wu Y; Wang HL; Xing W; Wang Y; Li C; Zhang ZJ; Wang ZL; Wang W; Han J BMC Complement Altern Med; 2017 Apr; 17(1):187. PubMed ID: 28372586 [TBL] [Abstract][Full Text] [Related]
19. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis. Wang KC; Yeh YT; Nguyen P; Limqueco E; Lopez J; Thorossian S; Guan KL; Li YJ; Chien S Proc Natl Acad Sci U S A; 2016 Oct; 113(41):11525-11530. PubMed ID: 27671657 [TBL] [Abstract][Full Text] [Related]
20. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis. Nishina H Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]